<DOC>
	<DOCNO>NCT02253420</DOCNO>
	<brief_summary>In summary , copanlisib metabolize mainly CYP3A4 enzyme , thus study evaluate potential DDI ( drug-drug interaction ) copanlisib concomitant CYP3A4 modulators Itraconazole ( CYP3A4 inhibitor ) Rifampin ( CYP3A4 inducer ) necessary . With regard study aim evaluate effect Itraconazole Rifampin absorbtion , distribution , metabolization elimination Copanlisib ( BAY80-6946 ) . In addition , parameter cardiovascular safety , effect copanlisib heart 's ability pump blood rule copanlisib 's potential causing specific type life-threatening arrhythmia , QT/QTc interval leave ventricular ejection fraction evaluate .</brief_summary>
	<brief_title>Copanlisib ( BAY80-6946 ) Drug-drug Interaction Cardiovascular Safety Study Advanced Solid Tumor Patients</brief_title>
	<detailed_description>The PI3K/AKT/mammalian target rapamycin ( mTOR ) pathway one prominent pathways promote cellular survival constitutively activate many type cancer . Class I PI3K receptor downstream cancer associate tyrosine kinase growth factor receptor . PI3K inhibitor expect effective PI3K pathway-driven tumor also combination chemotherapy agent . The management metabolic effect issue must address development anticancer agent target PI3K-Akt-mTOR pathway . Copanlisib ( BAY 80-6946 ) novel PI3K inhibitor develop treatment advanced refractory malignancy .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Male female patient ≥ 18 year age histological cytological confirm advanced solid tumor progress , fail respond , therapy know provide clinical benefit may enrol signing informed consent . Normal leave ventricular ejection fraction ; adequate liver , renal bonemarrow function assess laboratory value . Adequate performance status life expectancy least 3 month . Solidtumor patient central nervous system ( CNS ) metastases treatment complete &lt; 3 month enrollment lesion unstable progress MRI scan perform within 1 month enrollment unstable symptom CNS metastasis . Evidence ventricular dysfunction congestive heart failure ( CHF ) history CHF great NYHA Class II Active coronary artery disease myocardial infarction within 6 month study entry ; newonset angina within 3 month study entry unstable angina ; cardiac arrhythmia require antiarrhythmic therapy . Prior diagnosis Type 1 2 diabetes mellitus , hyperglycemia ( define fast blood plasma glucose 125 mg/dL 2 separate day , correspond 6.94 mmol/L ) HbA1c ≥ 7 % . Use systemic include inhaled corticosteroid within 2 day start study treatment ( however , topical steroid permit ) . Known presence human immunodeficiency virus ( HIV ) infection active hepatitis ( B C ) . Any ongoing medical , psychological social condition ( ) may interfere subject 's participation study evaluation study result . Known suspect allergy hypersensitivity copanlisib and/or itraconazole rifampin Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg despite optimal medical management ) . Anticancer chemotherapy , hormone therapy immunotherapy within 4 week first study treatment schedule administration ( ) study History , concurrent , interstitial lung disease ( ILD ) severely impaired pulmonary function . Medications drugdrug interaction potential itraconazole exclude study Cycle 1 CYP3A4 substrate narrow therapeutic window potential prolong QTc Ongoing cytomegalovirus infection confirm positive polymerase chain reaction cytomegalovirus Concomitant medication contraindicate use rifampin ( include , limited ) : cisapride , oral midazolam , nisoldipine , pimozide , quinidine , dofetilide , triazolam , levacetylmethadol ( levomethadyl ) , 3hydroxy3methylglutaryl coenzyme A ( HMGCoA ) reductase inhibitor metabolise CYP3A4 , lovastatin simvastatin , ergot alkaloid metabolise CYP3A4 , dihydroergotamine , ergometrine ( ergonovine ) , ergotamine methylergometrine ( methylergonovine ) , atazanavir , darunavir , fosamprenavir , ritonavirboosted saquinavir , saquinavir , tipranavir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>PI3 Kinase inhibitor</keyword>
	<keyword>Drug-drug Interaction</keyword>
</DOC>